• We are catalysts for innovation, commercialising next-generation technologies developed by

    The University of Manchester’s world-class research base





    • £360m+ invested by venture funders

    • 40+ spin-out companies created

    • 7,500+ licences and IP partnerships concluded

    • 4,000+ invention disclosures received

    • £115m+ IP and R&D revenue generated for the University







  • We are catalysts for innovation, commercialising next-generation technologies developed by The University of Manchester’s world-class research base





    • £300m+ invested by venture funders since 2004

    • 40+ spin-out companies created

    • 4,800+



      licences and IP partnerships concluded

    • 3,700+ invention disclosures received

    • 1,300+ jobs generated across various industry sectors

    • £105m+ IP and R&D revenue generated for the University


Posts Tagged ‘spin-outs’

New University of Manchester spin-out, Spectromics Limited, set to develop novel technology for effective use of antibiotics and other antimicrobial therapeutics

Manchester, UK  07/04/2014: University of Manchester spin-out, Spectromics Limited, is set to develop novel technology that will help guide the effective use of antibiotics and other antimicrobial therapeutics.

The formation of Spectromics is the result of three years of research by Professor Roy Goodacre of the Institute of Biotechnology and School of Chemistry at The University of Manchester, and Dr Mathew Upton, School of Biomedical and Healthcare Sciences, Plymouth University Peninsula Schools of Medicine and Dentistry, formerly at the School of Inflammation and Repair at The University of Manchester. Both are Directors of the company.

The technology, relating to rapid diagnostics for antimicrobial susceptibility testing, will allow doctors to determine the most effective drug to be prescribed for each patient, bringing a personalised medicine approach to the widespread use of antibiotics.

Growing resistance to antimicrobials is a global threat to the successful treatment of bacterial infections. This is a problem that is recognised by all of the major nations; the UK Chief Medical Officer stated that it is one of the three biggest threats to human health and it featured at last year’s G8 conference as a threat ranked alongside terrorism. Resistance to antibiotics is exacerbated by the current practice of issuing “best guess” prescriptions without knowing whether the patient actually has a bacterial infection, and whether that particular infection may be resistant to the drug being prescribed.

To run tests today to determine whether a drug is required and which is most effective takes days in a microbiology lab. The Spectromics technology will allow a doctor to run a 10 minute test which will indicate if an antibiotic is required, and if so, which one. The test will comprise of a small instrument and a cartridge into which the sample is added.

Over the next three years Spectromics will develop the commercial system for the first application. This will be for urinary tract infection which is the most prevalent bacterial infection affecting human health. Following this, other test specific cartridges for other clinical applications will follow.

Neil Butler, CEO of Spectromics commented: “I have been the CEO from formation of two other companies in the past, Vivacta and Oxford Biosensors, and worked in Point-of-Care diagnostics for fifteen years. What really excites me about Spectromics is the compelling need for a diagnostic that guides antibiotic treatment at the point-of-prescription. This technology is very differentiated as nothing else comes close to our test turnaround time. We are planning to raise significant investment, so that we can build the organisation rapidly, which in turn will bring the commercial system to market ASAP. This product was needed yesterday and we are going to make this technology the answer to the global call for a solution to antimicrobial stewardship.”

Stephen France of UMIP, the University of Manchester’s agent for Intellectual Property commercialisation, added: “The lack of new antibiotics, that has caused a 30 year discovery void, is alarming as our established drugs have a growing resistance making them ineffective in treating infections. The worry is that what have in the past been easily treated bacterial infections could in future be untreatable and life threatening. There are solutions to this problem: new antibiotics, and better stewardship of the ones we have, and we believe that both solutions are required for an effective remedy of the problem. When we saw the speed of this technology we knew it was a winner and this why we didn’t hesitate to build a business to exploit it fully.”

Contact Spectromics: email neil@meddx.co.uk 

www.spectromics.com

UMIP becomes key partner of non-profit global mentorship network

img0The world’s largest not-for-profit global mentorship and education network The Indus Entrepreneurs (TiE) has joined forces with UMIP, the University of Manchester’s agent for intellectual property commercialisation.

The pairing will see up to 35 student, spin-out or social enterprises from the University given the opportunity to access the TiE mentorship programme in both local sessions and by remotely connecting to TiE’s global network of business experts.

Regional sessions will be held at Founders Dock hub or in Quay House, Spinningfields – a new incubator that offers start-ups a range of support, including office space, technology and coaching from industry experts.

Organisations from UMIP will be invited to attend an on-going calendar of TiE events, seminars and workshops and will enjoy connections with the entire network, offering the opportunity for collaborations, the validation of business models and funding links.

Participating enterprises will also gain access to Founders Dock and will be able to utilise hot-desking, state-of-the-art technology and amenities like printers and web conferencing.

The collaboration will also entail:

• TiE mentors and speakers attending and presenting at UMIP events
• Related workshops at UMI3 (the University of Manchester Innovation Company)
• Student groups working alongside TiE mentors
• Collaborations of press, communications and media from the two organisations.

The relationship between the two organisations was driven by University of Manchester alumnus Vikas Shah, managing director of the Swiscot Group and Vice-President and Board Member for TiE’s branch in the north of the UK. He said: “Being a University of Manchester alumnus I was keen to develop links between the University and TiE. We are in an innovation economy, where the future global business success stories will be those driven by technology, intellectual property and science. UMIP and The University of Manchester are globally respected in this regard, and we are proud to be partnered with them.”

Tony Walker, Director of Enterprise and Business Development at UMIP, also welcomed the partnership, stating: “This partnership enables us to provide both our student and academic entrepreneurs with access to successful business mentors on a global scale. Access to such a successful TiE resource will be invaluable in helping them gain a greater understanding of their particular market characteristics and developing additional resource capability. “

logos TiE

CONTACT US